Our pipeline includes investigational therapies with demonstrated potential to address unmet needs in central nervous system (CNS) disorders including opioid use disorder (OUD), spasticity and narcolepsy.
PRECLINICAL
Cebranopadol
The first and only investigational dual nociceptin/orphanin FQ peptide (NOP) receptor and µ-opioid peptide (MOP) receptor agonist in clinical development for the treatment of OUD
In addition to treating pain, cebranopadol has the potential to be a best-in-class treatment for OUD as demonstrated in validated preclinical models, in which the drug blocked self-administration of morphine, heroin and cocaine. Investigation of cebranopadol in OUD is supported by a grant received by the National Institute on Drug Abuse (NIDA).
PHASE 1
TRN-213
An optimized formulation designed to improve the delivery of the current standard of care for patients with spasticity associated with multiple sclerosis and other diseases such as cerebral palsy
TRN-213 is designed to offer an extended-release treatment option, helping patients to achieve more consistent daily efficacy, higher adherence and a reduction in side effects.
PHASE 2
TRN-257
An investigational therapy for the treatment of narcolepsy, uniquely designed to provide clinically superior treatment as compared to existing options
Currently available treatments, which contain high levels of sodium oxybate, are suboptimal due to dosing (requiring patients to take a second dose in the middle of the night), safety issues and significant side effects that impact an individual’s quality of life. TRN-257 is designed to significantly improve the patient experience, containing very low sodium content and once-nightly dosing.